Technical Analysis for CLBS - Caladrius Biosciences, Inc.

Grade Last Price % Change Price Change
grade D 2.71 -2.17% -0.06
CLBS closed down 2.17 percent on Friday, November 15, 2019, on 2.37 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical CLBS trend table...

Date Alert Name Type % Chg
Spinning Top Other 0.00%
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Weak + Overbought Other 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
MACD Bullish Centerline Cross Bullish -2.17%

Older signals for CLBS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in New York, New York.
Banking Biopharmaceutical Cancer Diabetes Immunotherapy Cancer Immunotherapy Metastatic Melanoma Clinical Services Acute Myocardial Infarction Treatment Of Metastatic Melanoma
Is CLBS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.44
52 Week Low 2.0
Average Volume 16,888
200-Day Moving Average 2.9646
50-Day Moving Average 2.3872
20-Day Moving Average 2.2585
10-Day Moving Average 2.334
Average True Range 0.1813
ADX 17.62
+DI 32.0991
-DI 11.5335
Chandelier Exit (Long, 3 ATRs ) 2.2961
Chandelier Exit (Short, 3 ATRs ) 2.5439
Upper Bollinger Band 2.6662
Lower Bollinger Band 1.8508
Percent B (%b) 1.05
BandWidth 36.103609
MACD Line 0.0629
MACD Signal Line -0.017
MACD Histogram 0.08
Fundamentals Value
Market Cap 25.55 Million
Num Shares 9.43 Million
EPS -11.27
Price-to-Earnings (P/E) Ratio -0.24
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.01
Resistance 3 (R3) 3.02 2.92 2.96
Resistance 2 (R2) 2.92 2.85 2.92 2.94
Resistance 1 (R1) 2.82 2.80 2.77 2.81 2.93
Pivot Point 2.72 2.72 2.70 2.72 2.72
Support 1 (S1) 2.62 2.65 2.57 2.61 2.49
Support 2 (S2) 2.52 2.60 2.52 2.48
Support 3 (S3) 2.42 2.52 2.46
Support 4 (S4) 2.41